Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Can Nanotech Be a Game-Changer for In Vitro Diagnostics?

This article was originally published in Start Up

Executive Summary

People have awakened to the opportunities in diagnostics. Molecular information offers the potential for increased test sensitivity, and reduced upfront sample prep using nanotechnology could provide the means for many gene- and protein-based diagnostic tests to transition out of the central lab. Nanotech may also enable the use of newly discovered or newly usable biomarkers. Finally, unlike the traditional point-of-care model, a new wave of nanotech-based instruments could bring testing even closer to the patient.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037530

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel